CAJ | 학술논문

目的：开发基于 TNF 功能表位的新型人源单链抗体。方法利用自主研制的鼠抗 TNF-α中和单抗 Z12能特异性识别 TNF-α的141~146位功能表位特性，通过理论模拟构建 TNF/抗体 Z12相互作用的复合物模型设计获得功能性拮抗肽（PT2、PT3、PT4、PT7）以及单域抗体 PTVH5（以人抗体可变区重链框架 VH5为支架合理展示 PT2、PT3、PT4），利用计算机辅助分子设计以及同源模建、分子对接方法，进一步合理选择人抗体可变区轻链框架（Vκ1）作为展示支架，通过构象判别、作用能比较以及识别区域确认并选择合适的连接肽设计新型单链分子 ScFv_AB1。结果理论分析发现，ScFv_AB1稳定性较好，识别 TNF-α的141~146功能位点（即 Z12识别的位点）。生物学实验证明， ScFv_AB1能与 TNF-α结合、抑制 TNF-α与TNFR 的结合、抑制 TNF-α介导的细胞毒作用。结论初步验证了“借助计算机模建，基于人抗体可变区的框架结构和拮抗肽设计单链抗体分子”的策略是可行的，从而为人源小分子抗体的制备提供了一条可供选择的途径。
목적：개발기우 TNF 공능표위적신형인원단련항체。방법이용자주연제적서항 TNF-α중화단항 Z12능특이성식별 TNF-α적141~146위공능표위특성，통과이론모의구건 TNF/항체 Z12상호작용적복합물모형설계획득공능성길항태（PT2、PT3、PT4、PT7）이급단역항체 PTVH5（이인항체가변구중련광가 VH5위지가합리전시 PT2、PT3、PT4），이용계산궤보조분자설계이급동원모건、분자대접방법，진일보합리선택인항체가변구경련광가（Vκ1）작위전시지가，통과구상판별、작용능비교이급식별구역학인병선택합괄적련접태설계신형단련분자 ScFv_AB1。결과이론분석발현，ScFv_AB1은정성교호，식별 TNF-α적141~146공능위점（즉 Z12식별적위점）。생물학실험증명， ScFv_AB1능여 TNF-α결합、억제 TNF-α여TNFR 적결합、억제 TNF-α개도적세포독작용。결론초보험증료“차조계산궤모건，기우인항체가변구적광가결구화길항태설계단련항체분자”적책략시가행적，종이위인원소분자항체적제비제공료일조가공선택적도경。
Objective Developed novel human single chain antibody which design based on the functional epitope of TNF. Methods In a previous study, we obtained a TNF-α neutralizing mAb Z12 and identified the epitope (i.e. from 141 to 146 aa in TNF-α) recognized by Z12. Moreover, we explored a series of TNF-α antagonist peptides (i.e. PT2, PT3, PT4 and PT7) and the single domain antibody PTVH5 (using human antibody frame work of variable region of heavy chain, i.e. VH5, as scaffold to display the peptides PT2, PT3 and PT4) based on the interaction between TNF-α and mAb Z12. In the present work, based on the computer-guide molecular design, homology modeling and molecular docking method, we used human antibody frame work of variable region of light chain (Vκ1) as dispalying scaffold and obtained a novel single chain antibody, named as ScFv_AB1, according to the conformation, binding energy and identified domain. Results Theoretical analysis showed that ScFv_AB1 was stable and recognized the position 141-146 of TNF-α (same as Z12). Biological experiments showed that ScFv_AB1 could bind to TNF-α, competitively inhibit the binding of mAb Z12 to TNF-α, block the binding of TNF-αto TNFR and inhibit TNF-induced cytotoxicity. Conclusion This study demonstrated that it is feasible to design novel single chain antibody based on human antibody consensus frameworks and antagonist peptides using computer-guided modeling method. It also provides an alternative way to obtain human small molecular antibody.